Navigation Links
Amsterdam Molecular Therapeutics Reports Half Year Results 2009
Date:8/12/2009

AMSTERDAM, August 13 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2009.

    Highlights

    - Start of the preregistration clinical trial with Glybera(R)
      in Canada following two previous clinical trials
    - Presentation of additional data indicating that Glybera(R) offers
      a clinically important health benefit, accomplished by a significant
      and clinically important reduction in the incidence of acute
      pancreatitis in patients
    - Significant progress in research and development for other
      pipeline projects including hemophilia B, Duchenne muscular dystrophy
      and Parkinson's disease
    - Key financial figures in line with guidance
    - Cash & cash equivalents of EUR 25 million at June 30, 2009

Results comparison

AMT's key financial figures are well within the budgets for the first semester and therefore remain in line with the guidance that the company has given for 2009. The operating loss increased to EUR 9.9 million for the six months ended June 30, 2009, from EUR 9.1 million for the same period in 2008. This difference is primarily due to the increase of research & development costs to EUR 7.1 million from EUR 5.8 million in the same period of 2008. This increase is particularly related to the clinical development and regulatory work on the company's lead product, Glybera(R), as well as increased staffing for this and other programs. General and administrative costs decreased to EUR 2.9 million, from EUR 3.3 million in the first half of 2008, primarily as a result of decreased advisor's fees.

The net loss for the half of 2009 was EUR 9.4 million, as compared to a net loss of EUR 8.1 million for the first half of 2008.

At June 30, 2009, AMT's cash and cash equivalents amounted to E
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
3. Amsterdam Molecular Therapeutics Part of Next Biotech Index
4. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
5. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
6. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
7. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. SAFC Supply Solutions(R) Announces Raw Materials Line Developed Specifically to Meet Molecular Diagnostics Manufacturing Requirements
11. Sorenson Molecular Genealogy Foundation to Protect Archived DNA Using Biomatricas Room Temperature Storage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 05, 2015 The next implants made ... the CE mark (European) approval. The CE mark is ... Association (EFTA) and the European Union. Following the Class ... granted to implants supplied by the Turkey-based company Osimplant ... , Osimplant's Cervical Expandable Bladed HA PEEK Cage line ...
(Date:3/4/2015)... 4, 2015 In an article published and ... for Health Security review the clinical aspects of diseases ... as bioweapons. The article, "Clinical Management of Potential Bioterrorism-Related ... website of the New England Journal of Medicine ... Toner , and Tom Inglesby—review the clinical management of ...
(Date:3/4/2015)... 04, 2015 USDM Life Sciences ... life sciences industry, hired David Blewitt as ... Cloud Compliance Services and Solutions at USDM Life Sciences ... applications while maintaining compliance with government regulations worldwide. ... an accomplished life sciences regulatory and IS compliance professional ...
(Date:3/4/2015)... , March 4, 2015 /CNW/ - Resverlogix Corp. ... has completed a collaborative research program with ...  Using Fast Collective Evolution Technology (FACET), Emerald ... all measurements obtained from each of 798 ... 2 clinical trials ASSERT, SUSTAIN and ASSURE. ...
Breaking Biology Technology:Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3Latest Clinical Information On Bioterrorism Threats 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4
... the first ... ... dollars, QUEBEC CITY, May 6 /PRNewswire-FirstCall/ - Atrium Innovations Inc.,(TSX: ATB), ... and nutrition industries, announced today,his financial results for the first quarter of ...
... MINRAD,International, Inc. (Amex: BUF ) today announced that ... aggregate of $40.0 million of senior,secured convertible notes with ... The notes pay an 8% coupon, have a 3 ... The aggregate net,proceeds of the notes, after deducting the ...
... Conn., May 5 VION PHARMACEUTICALS,INC. (Nasdaq: VION ... March 31, 2008., The Company reported a net ... three-month period ended March 31, 2008, compared with a ... the same period in 2007.,Weighted-average common shares outstanding for ...
Cached Biology Technology:Atrium shows a strong financial performance for its first quarter 2Atrium shows a strong financial performance for its first quarter 3Atrium shows a strong financial performance for its first quarter 4Atrium shows a strong financial performance for its first quarter 5MINRAD International, Inc. Announces $40.0 Million Private Placement 2MINRAD International, Inc. Announces $40.0 Million Private Placement 3Vion Reports 2008 First Quarter Results 2Vion Reports 2008 First Quarter Results 3Vion Reports 2008 First Quarter Results 4
(Date:2/10/2015)... Inc. (NYSE: ALR), a global leader in rapid ... ended December 31, 2014. Namal Nawana, ... "We made substantial progress in the fourth quarter ... rapid diagnostics and delivering against our financial plans.  ... January enabled us to substantially reduce our debt, ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
(Date:2/5/2015)... 27, 2015   Marvin Test Solutions ... innovative test solutions for military, aerospace, and ... its TS-323 GENASYS Test Platform ... GENASYS is a high-performance PXI-based system designed ... that require performance functional testing. GENASYS features ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... the developing world, has announced the winners of the TWAS ... and be invited to lecture about his or her research ... place in Mexico City from 10 to 13 November 2008. ... Environmental Sciences, University of Agriculture, Faisalabad, Pakistan, has won the ...
... LAFAYETTE, Ind. - Pre-malignant mammary lesions in dogs and ... that could lead to better understanding of breast cancer ... Purdue University scientist from the School of Veterinary Medicine. ... found similarities between benign lesions that are considered to ...
... 2007 The American Physiological Society (APS; ... its prestigious Bodil M. Schmidt-Nielsen Distinguished Mentor and Scientist ... of Mississippi Medical Center. The honor, now in ... APS who have made outstanding contributions to physiological research ...
Cached Biology News:TWAS announces 2007 prize winners 2TWAS announces 2007 prize winners 3TWAS announces 2007 prize winners 4Purdue research finds similarities in dog, human breast cancer pre-malignant lesions 2Purdue research finds similarities in dog, human breast cancer pre-malignant lesions 3Purdue research finds similarities in dog, human breast cancer pre-malignant lesions 4Granger wins Schmidt-Nielsen Mentor/Scientist Award 2
...
Luminometers...
... Designed for serial preparation ... fractions including cytosol/particulate/cytoskeleton/nuclear fractions ... these fractions can directly ... assays such as 2-D ...
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
Biology Products: